Medizinische Universität Innsbruck
Innsbruck, Austria
11 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Advanced Breast Cancer
MedSIR240 enrolled69 locationsNCT06382948
Recruiting
Phase 3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Leiomyosarcoma
PharmaMar450 enrolled94 locationsNCT06088290
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled344 locationsNCT06819878
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Type 1 Diabetes
SAb Biotherapeutics, Inc.159 enrolled65 locationsNCT07187531
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Acute Myeloid Leukemia (AML)MDS/AML
University of Ulm50,000 enrolled94 locationsNCT01252485
Recruiting
Phase 3
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube NeoplasmsOvarian Neoplasm Epithelial+3 more
Swiss GO Trial Group540 enrolled53 locationsNCT04111978
Recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Multiple Myeloma (MM)Chronic Lymphocytic Leukaemia (CLL)Secondary Immunodeficiency (SID)
Medical University Innsbruck120 enrolled5 locationsNCT06821880
Recruiting
Phase 2Phase 3
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Kartos Therapeutics, Inc.268 enrolled83 locationsNCT05797831